Alexion Reports Second Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Pharma (ALXN) Tops Q2 EPS by 37c, Offers FY Guidance
July 26, 2018 6:36 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q2 EPS of $2.07, $0.37 better than the analyst estimate of $1.70. Revenue for the quarter came in at $1.05 million versus the consensus estimate of $977.68 million.
GUIDANCE:
Alexion Pharma sees FY2018 EPS of $7.00-$7.15, versus the consensus of... More
